SUMMARY
OBJECTIVE To develop and validate a prediction model, based on clinical history and examination findings on initial diagnosis of COVID-19, to identify patients at risk of critical outcomes.
DESIGN National multicenter cohort study.
SETTING Data from the SEMI (Sociedad Española de Medicina Interna) COVID-19 Registry, a nationwide cohort of consecutive COVID-19 patients presenting in 132 centers between March 23 and May 21, 2020. Model development used data from hospitals with ≥300 beds, and validation used those from hospitals with <300 beds.
PARTICIPANTS Adults (age ≥18 years) presenting with COVID-19 diagnosis.
MAIN OUTCOME MEASURE Composite of in-hospital death, mechanical ventilation or admission to intensive care unit.
RESULTS There were 10,433 patients, 7,850 (main outcome rate 25.1%) in the model development cohort and 2,583 (main outcome rate 27.0%) in the validation cohort. The clinical variables in the final model were: age, cardiovascular disease, moderate or severe chronic kidney disease, dyspnea, tachypnea, confusion, systolic blood pressure, and SpO2 ≤93% or supplementary oxygen requirement at presentation. The model developed had C-statistic of 0.823 (95% confidence interval [CI] 0.813 to 0.834) and calibration slope of 0.995. The external validation had C-statistic of 0.792 (95% CI, 0.772 to 0.812) and calibration slope of 0.872. The model showed positive net benefit in terms of hospitalizations avoided for the predicted probability thresholds between 3% and 79%.
CONCLUSIONS Among patients presenting with COVID-19, easily-obtained basic clinical information had good discrimination for identifying patients at risk of critical outcomes, and the model showed good generalizability. A model-based online prediction calculator provided with this paper would facilitate triage of patients during the pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research did not receive external funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Authors declare that all relevant ethical guidelines have been followed, all necessary IRB and/or ethics committee approvals have been obtained, all necessary patient/participant consent has been obtained and the appropriate institutional forms archived.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available on request from the SEMI-COVID-19 Registry Coordinating Center, S&H Medical Science Service and the corresponding author, [LM].
